BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Solutia, Inc. (SOI) Rejects Pharmacia Corporation (PFE) Settlement Costs Of Two Asbestos Cases


10/19/2005 5:09:22 PM

ST. LOUIS, Dec. 2 /PRNewswire-FirstCall/ -- Solutia Inc. today notified Monsanto and Pharmacia that it would not be making a $3 million payment to satisfy litigation settlements in two asbestos cases brought against Pharmacia. Solutia's only obligation related to this litigation comes as a result of its contractual obligation to indemnify legacy liabilities of the old Monsanto chemical business which were assigned to Solutia at the time of Solutia's creation in 1997. Solutia has given notice to Monsanto and Pharmacia to enable them to make the required payments on their own behalf.

When Solutia was spun off from Monsanto in 1997, Monsanto contractually obligated Solutia to bear the responsibility for hundreds of millions of dollars of legacy liabilities that accrued to Monsanto and its successor, Pharmacia, over a century of manufacturing, primarily in the areas of retiree benefits, environmental cleanup and litigation defense costs. In its 2003 third quarter 10-Q filing, Solutia disclosed that it must take action to reduce its current level of legacy liabilities, which currently cost Solutia approximately $100 million annually.

Solutia has not advised Monsanto and Pharmacia that it will not honor any remaining legacy liabilities. In fact, Solutia continues to make other selected legacy liability payments. As individual legacy liability payments come due, Solutia will evaluate whether it is prudent for it to make those payments and will, in all cases where it determines to not make such payments, notify Monsanto and Pharmacia to enable them to pay their obligations.

Corporate Profile

Solutia ( http://www.solutia.com/ ) uses world-class skills in applied chemistry to create value-added solutions for customers, whose products improve the lives of consumers every day. Solutia is a world leader in performance films for laminated safety glass and after-market applications; process development and scale-up services for pharmaceutical fine chemicals; specialties such as water treatment chemicals, heat transfer fluids and aviation hydraulic fluid and an integrated family of nylon products including high-performance polymers and fibers.

Solutia ... Solutions For a Better life.

Solutia Inc.

CONTACT: Media, Glenn Ruskin, +1-703-282-7429, or Financial, MarleenJudge, +1-314-674-7777, both for Solutia



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES